厄比奎蒂 UI 深 沪
已收盘 12-19 16:00:00 美东时间
564.62
+12.950
+2.35%
华盛通- 最 高565.66
- 今 开550.80
- 成交量 20.80万股
- 最 低 546.00
- 昨 收 551.67
- 总市值 341.55亿
- 52周最高 802.795
- 市盈率 静 48.01
- 换手率 0.34%
- 52周最低 252.80
- 委 比 -4.55%
- 总股本 6049.12万
- 历史最高 802.795
- 量 比 2.79
- 振 幅 3.56%
- 历史最低 93.52
- 每 手 1
- 风险率 134.37%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Shares of companies within the broader technology sector are trading lower amid weakness in Broadcom after it issued cautious outlook. The sector is also being weighed down by reports that Oracle delayed some data center projects for OpenAI.
Shares of companies within the broader technology sector are trading lower amid...
12-13 04:20
美股大行评级 | CoreWeave、Monday遭美银、小摩等多家大行下调目标价；中金首予Nebius "跑赢大市"评级，目标价143美元
今日重点评级关注：Piper Sandler：维持MeiraGTx Hldgs"超配"评级，目标价从28美元升至30美元；RBC Capital：维持4D Molecular Therapeutics"跑赢大市"评级，目标价从26美元升至32美元
11-12 11:43
Barclays Maintains Underweight on Ubiquiti, Raises Price Target to $455
Barclays analyst Tim Long maintains Ubiquiti (NYSE:UI) with a Underweight and raises the price target from $299 to $455.
11-11 23:40
A Look Ahead: Cisco Systems's Earnings Forecast
Cisco Systems (NASDAQ:CSCO) is preparing to release its quarterly earnings on W...
11-11 22:01
Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia
Transition Bio and Voyager Therapeutics have entered a collaboration to develop small molecules targeting TDP-43 pathology for ALS and FTD. Transition Bio will handle discovery and optimization, with Voyager having an option to license the program. Transition Bio received an upfront payment and is eligible for up to $500M in milestones plus royalties. The collaboration aims to address TDP-43's role in neurodegenerative diseases, leveraging Transi...
11-10 13:01
Ubiquiti Networks Inc. Reports Strong Quarterly Growth
Ubiquiti Networks Inc ( ($UI) ) has released its Q1 earnings. Here is a breakdo...
11-08 12:16
Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition
Agios Pharmaceuticals announced new data on mitapivat, a pyruvate kinase activator, to be presented at ASH 2025. The data highlights its potential in treating thalassemia, sickle cell disease, and PK deficiency. Key findings include subgroup analysis showing 77.8% of alpha-thalassemia patients achieved transfusion reduction, long-term transfusion-free periods up to 84.3 weeks, and positive results from the ACTIVATE-Kids trial in pediatric PK defi...
11-03 14:01
Nasdaq 100 Rebounds, Amazon Jumps 10% On Strong Earnings: What's Moving Markets Friday?
Tech stocks edged higher Friday, rebounding from Thursday's 1.5% drop in the Nasdaq 100 as upbeat earnings from mega-cap giants kept the rally momentum alive.
11-01 01:26
